Article By:
Vivian Lewis
Monday, August 31, 2020 10:00 PM EDT
Buffett's new stake in five Japanese trading groups earned me a tidy profit. Meanwhile GSK and its partner Vir have begun enrolling people for the Comet-ICE antibody trial in phase II-III which expects to see results by the end of this year.
In this article: EXG, GSK, SLB, ITOCY, MARUF, SSUMY, HSNGF, MITSY, MSBHF, TMRAY, TEVA, CGEN, GLD, VEOEY, HMLP, KL, NOK, VOD, NIO, AZRE, BRK-A, BRK-B